Benralizumab Arm B

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Phase 3

Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History

CompletedNCT02138916

AstraZenecaModerate to Very Severe Chronic Obstructive Pulmonary Disease

Start: 2014-06-13End: 2018-04-10Updated: 2019-06-13

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History

CompletedNCT02155660

AstraZenecaModerate to Very Severe Chronic Obstructive Pulmonary Disease

Start: 2014-06-25End: 2018-04-09Updated: 2019-06-26

Related Papers

Pharmacodynamic Effects of Benralizumab on Eosinophil-related Biomarkers in COPD: A Biomarker Analysis of the GALATHEA Study

American Journal of Respiratory and Critical Care Medicine2025-05-011 citations

Effect of benralizumab treatment on the airway microbiome in COPD

ERJ Open Research2024-11-072 citations

Benralizumab increases time to recurrent exacerbations in COPD patients on triple therapy with frequent exacerbations and an eosinophilic phenotype

2023-09-09

Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis

International Journal of COPD2023-07-0125 citations

Effect of benralizumab on recurrent COPD exacerbations

05.01 - Airway pharmacology and treatment2022-09-041 citations

Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies.

2019-09-2879 citations

Benralizumab for the Prevention of COPD Exacerbations

New England Journal of Medicine2019-05-20311 citations

Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD

BMJ Open Respiratory Research2016-09-0142 citations